U.S. Entertainment Stock News

Nutex Health reported past first-quarter 2026 results on April 30, with revenue of US$216.49 million and net income of US$46.81 million, lifting both basic and diluted earnings per share from continuing operations versus a year earlier. Alongside these results, the company announced a second US$25.00 million share repurchase program and a shift toward directly developing new hospital facilities, signaling a material change in how it funds and expands its footprint. We’ll now examine how...

Wondering whether AngloGold Ashanti at around US$98.60 is still offering value after a strong run, or if most of the easy gains are already behind it. The stock has been volatile recently, with a 9.0% return over the last 7 days, a 2.8% decline over 30 days, a 15.2% return year to date, and a 136.0% return over the last year, alongside very large multi year gains of around 3x over 3 years and nearly 4x over 5 years. Recent coverage has focused on AngloGold Ashanti's position within the...

Ferguson Enterprises Q1 2026 headline numbers Ferguson Enterprises (FERG) opened fiscal Q1 2026 with revenue of about US$7.5b and basic EPS of US$2.13, setting a clear marker for how the business is starting the new financial year. The company has seen quarterly revenue move from roughly US$7.2b in Q1 2025 to about US$7.5b in Q4 2025 and then US$7.5b in Q1 2026. Basic EPS has shifted from US$1.74 to US$1.99 and then US$2.13 over the same periods, giving investors a view on how earnings are...

Why Regal Rexnord’s leadership change and upcoming earnings matter now Regal Rexnord (RRX) has drawn fresh attention after the board named Aamir Paul as incoming CEO by July 2026 and investors look ahead to Q1 results, where the market expects a return to revenue growth. See our latest analysis for Regal Rexnord. The recent 4.21% 1 day share price return and 24.84% 30 day share price return, on top of a 79.77% 1 year total shareholder return, suggest momentum has been building as investors...

Microchip Technology (MCHP) has drawn attention after a strong run over the past month, with the stock up 50.1%, alongside full year revenue of US$4.37b and a reported net loss of US$154.4m. See our latest analysis for Microchip Technology. Beyond the past month’s surge, Microchip Technology’s share price has a 7 day share price return of 16.9% and a year to date share price return of 51.4%. The 1 year total shareholder return of 114.7% points to strong recent momentum. If this kind of move...

JBT Marel (JBTM) has just put fresh numbers on the table for Q1 2026, coming off Q4 2025 revenue of about US$1.0 billion and basic EPS of US$1.02, against a trailing twelve month picture that includes a basic EPS loss of US$0.96 on US$3.8 billion of revenue. Over the past few quarters, the company has seen quarterly revenue move from US$453.8 million in Q3 2024 to US$854.1 million in Q1 2025 and then to roughly US$1.0 billion by Q4 2025. EPS swung from US$1.19 in Q3 2024 to a loss of US$3.35...

With NRG Energy last closing at US$150.64, this article looks at whether the stock is still priced for opportunity or already reflects most of its story, and what that may mean for you as an investor. The stock has returned 1.1% over the last 7 days and 0.6% over the last 30 days, with a year-to-date decline of 9.3% and a 28.4% return over the last year, alongside a very large gain over 5 years. Recent coverage has focused on NRG Energy's position within the US utilities sector and how its...

Venture Global (NYSE:VG) has taken a final investment decision on Phase 2 of its CP2 LNG project and secured project financing, reducing construction and cash flow risks. The company reached a commercial settlement with Edison related to Calcasieu Pass arbitration, addressing an outstanding legal dispute. Venture Global signed a new binding LNG purchase agreement with Vitol for five years starting in 2026. For investors watching US LNG developers, Venture Global sits at the intersection of...

If you are wondering whether Floor & Decor Holdings at around US$51 a share is attractively priced or a potential value trap, the starting point is understanding how the current market price lines up against different measures of value. The stock has recently moved 7.0% over the last week and 3.3% over the last month, while the year to date return sits at a 19.0% decline and the 1 year return at a 30.5% decline, which may catch the eye of investors weighing up risk and recovery...

Gartner (IT) has put fresh numbers on the board for Q1 2026, reporting revenue of US$1.5b and basic EPS of US$3.19 off net income of US$222.3m, setting the tone for how you might think about the rest of the year. Over recent quarters the company has seen revenue move between US$1.5b and US$1.8b, while quarterly EPS has ranged from US$0.47 to US$5.14, providing a clear view of how earnings power has fluctuated into this latest print. With trailing net margins now sitting well below last year’s...

If you are wondering whether SoFi Technologies at around US$16.30 is starting to look expensive or still offers value, it helps to step back and look at what the recent price action and fundamentals are really saying. The stock has seen mixed returns, with a 5.0% move over the last 7 days, 0.2% over 30 days, a 40.6% decline year to date, and a 25.3% return over the past year. These shifts can change how investors think about both its growth potential and risk. Recent coverage has focused on...

If you are wondering whether NuScale Power's current share price reflects its true worth, this article will help you size up the stock using several valuation tools. The stock recently closed at US$11.87, with returns of 0.4% over 7 days, 16.9% over 30 days, a 27.2% decline year to date, a 32.8% decline over 1 year, 47.6% over 3 years and 19.8% over 5 years. This gives you a wide range of outcomes to think about. Recent coverage has focused on NuScale Power's role in nuclear energy...

Guardant Health’s Guardant360 CDx liquid biopsy has received FDA approval as a companion diagnostic for VEPPANU, a therapy for ER+/HER2- advanced breast cancer with ESR1 mutations. This is the third ESR1 companion diagnostic approval tied to Guardant360 CDx, further linking the test to targeted breast cancer treatments. The new approval broadens the clinical use of Guardant360 CDx and deepens Guardant Health’s ties with pharmaceutical partners. For investors tracking Guardant Health...

Alkermes Q1 2026 earnings: setting the stage Alkermes (ALKS) heads into Q1 2026 following its Q4 2025 report, where revenue was US$384.5 million and basic EPS came in at US$0.30, with net income excluding extra items of US$49.3 million. Over recent quarters, the company has reported revenue of US$429.99 million in Q4 2024, US$390.7 million in Q2 2025, and US$394.2 million in Q3 2025. Quarterly basic EPS over that period was US$0.90 in Q4 2024, US$0.50 in Q3 2025, and US$0.30 in Q4 2025. These...

Seadrill stock snapshot after recent performance Seadrill (SDRL) has drawn fresh attention after recent trading, with the stock last closing at US$48.90 and showing mixed short term returns, including a 0.9% decline over the past day and 1.8% decline over the past week. See our latest analysis for Seadrill. While Seadrill’s 1 day and 7 day share price returns are slightly negative, the 30 day and 90 day share price returns of 7.2% and 23.5%, together with a 1 year total shareholder return of...

Revvity Q1 2026 earnings snapshot Revvity (RVTY) has just put fresh numbers on the table, with recent quarters showing revenue between US$664.8 million and US$772.1 million and basic EPS ranging from US$0.35 to US$0.85 as the company heads into its Q1 2026 update. Over the past year, revenue has been recorded from US$684.0 million in Q3 2024 up to US$772.1 million in Q4 2025, while basic EPS prints in that stretch run from US$0.35 to US$0.85, giving investors a clear view of how the top line...

Clinical partnership puts Vir Biotechnology in focus Vir Biotechnology (VIR) has drawn fresh attention after finalizing its collaboration with Astellas Pharma on VIR-5500 for prostate cancer and treating the first patient in an expansion cohort of its Phase 1 metastatic prostate cancer trial. See our latest analysis for Vir Biotechnology. The recent collaboration news comes against a backdrop of strong momentum, with a 30 day share price return of 10.49% and a year to date share price return...

Two Harbors Investment (NYSE:TWO) is the subject of a takeover battle involving competing bids from UWM Holdings and CrossCountry Mortgage. The board of NYSE:TWO has rejected multiple acquisition attempts from UWM Holdings and is backing a fully financed, all-cash offer from CrossCountry Mortgage. The contest now centers on a shareholder vote, proxy solicitations, and competing arguments about value, deal structure, and execution risk. For you as a NYSE:TWO shareholder, this is not a...

Wondering if Ally Financial at around US$43 per share still offers value, or if most of the easy gains are behind it, starts with understanding what the current price is actually reflecting. The stock has had mixed recent returns, with a 2.7% decline over the last week, an 8.5% gain over the last month, a 5.6% decline year to date, and a 36.8% return over the last year alongside an 88.9% three year return and a 2.9% five year decline. Recent coverage has focused on how Ally Financial fits...

Avista’s Q1 2026 earnings in focus Avista (AVA) has rolled into Q1 2026 on the back of a solid run through 2025, capped by Q4 revenue of US$533 million and basic EPS of US$0.87, alongside trailing 12 month EPS of US$2.38 on US$1.96 billion of revenue. Over recent quarters, the company has seen revenue hold in a US$394 million to US$617 million range while quarterly EPS moved between US$0.17 and US$0.98. The trailing net profit margin is 9.8% compared with 9.3% a year earlier, which puts the...

In the past quarter, Adaptive Biotechnologies reported first‑quarter 2026 revenue of US$70.87 million, up from US$52.44 million a year earlier, while narrowing its net loss to US$20.03 million and reducing basic loss per share from US$0.20 to US$0.13. The results were powered by Minimal Residual Disease testing, with clonoSEQ volumes rising strongly and management raising full‑year 2026 MRD revenue guidance to US$260–US$270 million, underscoring the segment’s growing importance to the...

AGCO (AGCO) has just opened Q1 2026 earnings season with recent quarterly numbers that plot a sharp swing in profitability, moving from a Q4 2024 net loss of US$255.7 million on US$2,887.3 million of revenue and EPS of US$3.43 loss, to Q4 2025 net income of US$95.5 million on US$2,920.2 million of revenue and EPS of US$1.29. Over the same period, trailing twelve month EPS shifted from a US$5.69 loss on US$11.7 billion of revenue to US$9.76 on US$10.1 billion. Revenue moved from US$2,599.3...

In late April 2026, Opera Limited reported past first-quarter 2026 results showing sales of US$175.77 million and net income of US$24.79 million, alongside higher basic and diluted EPS of US$0.27 from continuing operations. On the same day, Opera raised its full-year 2026 revenue outlook to US$727 million–US$740 million and projected robust double-digit year-over-year growth for both the second quarter and the full year, highlighting management’s confidence in the business. With Opera...

Investors may be wondering if ConocoPhillips at around US$123.32 still offers value after a strong run, or if recent enthusiasm has already been priced in. The stock has seen a 27.5% return year to date and 45.5% over the last year, even though the last 7 days and 30 days showed returns of a 0.8% decline and a 5.5% decline, respectively. Recent coverage has focused on ConocoPhillips as a major integrated energy producer, with attention on how it is positioning its portfolio and capital...